Other substances

Genz-667161

A glucosylceramide synthase inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Genz-667161 is a glucosylceramide synthase inhibitor and venglustat analogue. It was shown to inhibit SARS-CoV-2 replication in vitro (Vitner et al., 2021).

 

Synonyms

Genz-161; GZ 161

 

Supporting references

Link Tested on Impact factor Notes Publication date
Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and Influenza virus
Small molecule In vitro 		Vero E6 cells; SARS-CoV-2 clinical isolate EPI_ISL_406862 [GISAID] 4.24

The compound inhibited SARS-CoV-2 infection with an IC50 of 2.5 μM and an SI of >19.2. It was active likely due to glucosylceramide synthase inhibition at the early stages of viral replication.

 Feb/24/2021
Export (.csv)